Zenas BioPharma, Inc.

0 products tracked · names used in filings: Zenas BioPharma, Inc.

Upcoming milestones

Thu 27 May 2027🇺🇸 PDUFA datecompany-announcedin 194 days

Obexelimab: PDUFA target action date (IgG4-RD)

Zenas BioPharma, Inc. (ZBIO); BLA; status: set; "Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update - PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 - - Obexelim"; filed 2026-11-05 · source

Recent milestones

No recent milestones.

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.